首页365bet娱乐官网网址365bet国际娱乐城365bet体育在线官电子期刊下载专区广告合作征稿启事留言板
位置:首页 >> 电子期刊 >> 正文
胃癌术后2种辅助化疗方案的疗效及安全性分析
作者:李晓芬  崔学芳  李晶晶  袁瑛 
单位:浙江大学医学院附属第二医院肿瘤内科  浙江 杭州 310009 
关键词:胃肿瘤/药物疗法 化学疗法 辅助 奥沙利铂/治疗应用 紫杉酚/治疗应用 回顾性研究 
DOI:R35.1;R730.53
出版年,卷(期):页码:2013,28(3):309-311
摘要:
目的 比较奥沙利铂联合5-FU或紫杉醇联合5-FU 2种化疗方案对胃癌根治术后患者的临床疗效和不良反应。方法 51例胃癌根治术后患者,37例接受奥沙利铂联合5-FU方案化疗(奥沙利铂组),14例接受紫杉醇联合5-FU方案化疗(紫杉醇组),随访2年。结果 47例患者有完整的随访资料。奥沙利铂组和紫杉醇组的1年无瘤生存率分别为72.7%和64.3%,2年无瘤生存率分别为72.7%和57.1%;1年生存率分别为87.9%和78.6%,2年生存率分别为78.8%和57.1%。奥沙利铂组的无瘤生存率、总生存率略高于紫杉醇组,但两者之间差异无统计学意义(P>0.05)。单因素分析显示男性患者的2年无瘤生存率和2年总生存率均显着高于女性患者(P<0.05)。2组患者不良反应均可耐受;奥沙利铂组Ⅲ~Ⅳ度恶心、呕吐、中性粒细胞减少、周围神经毒性发生率多于紫杉醇组,差异无统计学意义(P>0.05)。结论 奥沙利铂联合5-FU或紫杉醇联合5-FU两种化疗方案是胃癌根治术后有效的辅助化疗方案,且不良反应可耐受,安全性高。
Objective To evaluate the efficacy and toxicity of combination regimens with oxaliplatin plus 5-fluorouracil (oxaliplatin-based subgroup) or paclitaxel plus 5-fluorouracil (paclitaxel-based subgroup) as post-operative adjuvant chemotherapy in advanced gastric cancer. Methods Fifty-one patients with radical gastrectomy were enrolled. Thirty-seven patients were enrolled in oxaliplatin-based subgroup, while the other 14 patients were enrolled in paclitaxel-based subgroup. All the patients were followed up for 2 years. Results Forty-seven gastric cancer patients from two groups had intact follow-up data. One-year disease free survival rate (DFS) of oxaliplatin-based subgroup and paclitaxel-based subgroup was 72.7% and 64.3%, and 1-year overall survival (OS) was 87.9% and 78.6%, respectively. Two-year DFS was 72.7% and 57.1%, and 2-year OS was 78.8% and 57.1%, respectively. Both DFS and OS in oxaliplatin-based subgroup was higher than those in paclitaxel-based subgroup, but there was no statistical significances (P>0.05). Univariate analysis showed that 2-year DFS and 2-year OS of males were significantly higher than those of females(P<0.05). No severe toxicity was observed in both groups. Grade Ⅲ~Ⅳ toxicity such as ne365bet娱乐官网网址utropenia, nausea and neurotoxicity in the oxaliplatin-based subgroup were more than those in the paclitaxel-based subgroup (P>0.05). Conclusion Oxaliplatin plus fluorouracil and paclitaxel plus fluorouracil are effective adjuvant chemotherapy regimens and well-tolerable after radical resection of gastric cancer.
文章下载】【加入收藏

浙ICP备18004413号

技术服务qq:1507079184(投稿系统问题可找我)

编辑部地址:浙江省杭州市上城区解放路88号(浙医二院内)

电话:0571-87783654 邮编:310009 E-mail:shyzhl@zju.edu.cn

期刊介绍 使用帮助 | 365bet体育在线官 | 留言板